Molecule News and Research

RSS

Research targets malignant glioma stem cells

Cleveland Clinic researchers have identified a cellular pathway that cancer stem cells use to promote tumor growth in malignant glioma, an aggressive brain tumor.

11 Jul 2011

New technique may help scientists probe mysteries of many different stem cells

Researchers at the Salk Institute have been able to genetically incorporate "unnatural" amino acids, such as those emitting green fluorescence, into neural stem cells, which then differentiate into brain neurons with the incandescent "tag" intact.

8 Jul 2011

New technique shields patients from toxic parts of antibiotic drug

A new technique which targets antibiotic-resistant bacteria and shields patients from the toxic parts of an antibiotic drug has been developed by Cardiff University scientists.

8 Jul 2011

New target could halt growth of glioblastoma

Researchers have uncovered a new target that could stop the growth of glioblastoma, a deadly form of brain cancer.

8 Jul 2011

Fused indolines made by asymmetrical carbon–carbon coupling

Many drugs are based on natural substances. Because it is usually difficult, if not impossible, to isolate these in sufficient quantities from plants or microorganisms, they must be synthesized in the laboratory. This requires linking carbon atoms – with the right spatial orientation (stereochemistry) relative to each other. In the journal Angewandte Chemie, E. Peter Kündig and a team from the University of Geneva (Switzerland) have now introduced a palladium-catalyzed synthesis that allows them to produce indoline derivatives with the correct spatial arrangement.

7 Jul 2011

Experiment to protect astronauts from bone loss during space travel

Astronauts lose a significant amount of bone mass during space travel and with long duration flights there is concern that this bone loss could lead to an increased risk of fractures.

7 Jul 2011

Researchers find new molecule that controls pain sensitivity from UVB irradiation

Researchers at King's College London have found a molecule in the body which controls sensitivity to pain from UVB irradiation, identifying it as a new target for medicines to treat pain caused by other common inflammatory conditions such as arthritis.

7 Jul 2011

Alpha-tocotrienol protects brain cells after stroke in three ways

A natural form of vitamin E called alpha-tocotrienol can trigger production of a protein in the brain that clears toxins from nerve cells, preventing those cells from dying after a stroke, new research shows.

6 Jul 2011

Researchers discover crucial role of miR-206 in skeletal muscle development

Research led by the University of East Anglia has discovered the crucial role of a molecule in skeletal muscle development.

5 Jul 2011

Genetically engineered pigs may help overcome donor organ shortage

A sizzling genetic discovery by Chinese scientists may one day allow pig tissue to be transplanted successfully into humans. Their research presented in the Journal of Leukocyte Biology (http://www.jleukbio.org) represents a major step forward toward filling the shortage of vital organs for human transplantation.

1 Jul 2011

The Max Cure Foundation, SWCRF partner to fund pediatric cancer research

The Max Cure Foundation and the Samuel Waxman Cancer Research Foundation have partnered to establish a fund in pediatric cancer research. With that goal in mind, the two Foundations are proud to announce the award of $100,000 to Erwin G. Van Meir, Ph.D., of Emory University School of Medicine in Atlanta.

1 Jul 2011

Six new scientists to receive SWCRF grants for cancer research

This year, the Samuel Waxman Cancer Research Foundation awarded individual grants to six new researchers in addition to funding 18 collaborative grants and three ongoing individual grants. The Foundation expanded its scientific grants program to a total of more than $3.1 million.

1 Jul 2011

Small molecule treatment holds promise for Usher syndrome

New treatment approach shall soon be ready for use in Usher syndrome patients / Publication in "Human Gene Therapy".

1 Jul 2011

Amylin behaves when guarded by zinc

In type 2 diabetes, a protein called amylin forms dense clumps that shut down insulin-producing cells, wreaking havoc on the control of blood sugar. But zinc has a knack for preventing amylin from misbehaving.

1 Jul 2011

Scientists discover enzyme that can regulate breast cancer development

Researchers at Cold Spring Harbor Laboratory (CSHL) have identified an enzyme that appears to be a significant regulator of breast cancer development. Called PTPN23, the enzyme is a member of a family called protein tyrosine phosphatases, or PTPs, that plays a fundamental role in switching cell signaling on and off.

1 Jul 2011

Positive topline results from Alkermes ALKS 9070 phase 1b study for schizophrenia

Alkermes, Inc. today announced positive topline results from a phase 1b, double-blind, randomized, placebo-controlled study of ALKS 9070 in patients with schizophrenia.

30 Jun 2011

TCGA examines ovarian serous adenocarcinoma tumors from 500 patients

An analysis of genomic changes in ovarian cancer has provided the most comprehensive and integrated view of cancer genes for any cancer type to date. Ovarian serous adenocarcinoma tumors from 500 patients were examined by The Cancer Genome Atlas (TCGA) Research Network and analyses are reported in the June 30, 2011, issue of Nature.

30 Jun 2011

Modulating interaction between 'rotten eggs' gas and nitric oxide may treat heart failure

Research carried out by scientists from the Peninsula Medical School at the University of Exeter and the National University of Singapore has analysed the complex 'cross talk' between hydrogen sulphide and nitric oxide, both gasses that occur naturally in the body, and found that the interaction may offer potential strategies in the management of heart failure.

30 Jun 2011

Acetylon to advance ACY-1215 drug candidate with $27M Series B Preferred equity investment round of financing

Acetylon Pharmaceuticals, Inc. announced today that it has completed a $27 million Series B Preferred equity investment round of financing.

29 Jun 2011

Threshold commences combination Phase 1/2 trial of TH-302 and sunitinib for RCC, GIST and PNET

Threshold Pharmaceuticals, Inc., today announced the initiation of a Phase 1/2 dose escalation clinical trial of TH-302 in combination with sunitinib in patients with advanced renal cell carcinoma (RCC), gastrointestinal stromal tumor (GIST) and pancreatic neuroendocrine tumor (PNET).

29 Jun 2011